Dr. Haşim Gezegen | Cognitive Neuroscience | Best Researcher Award

Experience

Midyat Public Hospital, Emergency Department
Practitioner
November 2017 to February 2018
Mardin, TurkeyHaydarpaşa Numune Research and Training Hospital, Neurology Department
Neurology Resident
February 2018 to February 2019
Istanbul, TurkeyIstanbul University Istanbul Faculty of Medicine, Neurology Department
Neurology Resident
2019 to February 2019
Istanbul, Turkey🏥

Department of Behaviour and Movement Disorders for 3 months🧠 Department of Demyelinating Diseases for 4 months🧠 Department of Cerebrovascular Diseases for 3 months🧠 Department of Epilepsy for 3 months🏥 Department of Acute Neurology for 6 months🦾 Department of Neuromuscular Diseases for 3 months🧠 Department of Neurology Intensive Care Unit for 5 months👩‍⚕️ General Neurology outpatient clinics for 6 months🦠 Coronavirus inpatient and outpatient clinics for 5 months🚑 Inpatient Consultation for 3 months🧠 Department of Electrophysiology, 3 months for EEG, 3 months for EMG❤️ Department of Cardiology for a month💪 Department of Physical Therapy and Rehabilitation for a month🌡️ Department of Intensive Care Unit for 2 months

Research Projects (Ongoing)

DNLI-H-0001
A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension – RaterALXN1720-MG-301
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis – RaterNCT04146051
Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG) – RaterEFC14028
A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naïve Patients with Late-onset Pompe Disease – Rater